Oxo Combination Treatment for EMT-Driven Adenocarcinoma Resistance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Drug resistance in adenocarcinomas, particularly pancreatic ductal adenocarcinoma (PDAC), is a significant challenge due to epithelial-to-mesenchymal transition (EMT) plasticity, which contributes to metastatic dissemination and intrinsic resistance to chemotherapy.

Innovation Solution

Administering (5z)-7-oxozeaenol (Oxo) or its analogs, optionally combined with chemotherapy regimens like FOLFIRINOX, to inhibit EMT plasticity and enhance chemotherapy sensitivity in adenocarcinoma cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy is administered alone, then treatment is simple, but drug resistance develops due to EMT plasticity

Engineering Contradiction:

Improvechemotherapy effectivenessVSAvoidtreatment regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines (5z)-7-oxozeaenol (Oxo) with chemotherapy regimens (e.g., FOLFIRINOX) to treat adenocarcinoma. This combination merges an EMT inhibitor with conventional chemotherapy, addressing the contradiction by improving chemotherapy effectiveness through synergistic action while accepting increased treatment complexity as a necessary trade-off for overcoming drug resistance.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent administers Oxo before or in combination with chemotherapy to pre-inhibit EMT plasticity and sensitize tumor cells to chemotherapy. This preliminary action prevents the development of resistance mechanisms, thereby improving the reliability of subsequent chemotherapy treatment.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If EMT plasticity is inhibited, then drug resistance is reduced, but treatment complexity increases

Engineering Contradiction:

Improvedrug therapy resistanceVSAvoidtreatment regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the biological state of tumor cells by administering Oxo, which inhibits EMT plasticity and alters gene expression profiles. This parameter change in cell state reduces drug resistance and improves treatment reliability, while the complexity of implementing this molecular intervention is accepted as necessary.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If (5z)-7-oxozeaenol is administered alone, then EMT plasticity is inhibited, but killing efficacy is reduced compared to combination therapy

Engineering Contradiction:

ImproveEMT plasticity inhibitionVSAvoidcell killing efficacy

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent merges Oxo with chemotherapy agents to achieve synergistic cell killing. While Oxo alone effectively inhibits EMT plasticity, the combination with chemotherapy provides enhanced cytotoxicity, resolving the contradiction by accepting that maximum killing efficacy requires combination therapy rather than monotherapy.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20250319061A1Combination treatment for adenocarcinoma

Publication Date: 2025.10.16 THE GENERAL HOSPITAL CORP

AI summary

Described herein are methods for treating a carcinoma in a subject, the method comprising administering to the subject a therapeutically effective amount of (5z)-7-oxozeaenol (Oxo) or an analog thereof, optionally in combination with chemotherapy.